Education
About Us
Working with TipRanks
Follow Us
Dexcom (DXCM)
NASDAQ:DXCM
DXCM Stock Chart & Stats
Day’s Range― - ―
52-Week Range$57.52 - $139.24
Previous CloseN/A
Volume488.69K
Average Volume (3M)4.89M
Market Cap
$25.93B
Enterprise Value$31.64B
Total Cash (Recent Filing)$10.70M
Total Debt (Recent Filing)$5.87M
Price to Earnings (P/E)46.4
Beta1.13
Next Earnings
May 01, 2025EPS Estimate
0.33Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.45
Shares Outstanding392,107,500
10 Day Avg. Volume5,772,300
30 Day Avg. Volume4,890,706
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)7.15
Price to Cash Flow (P/CF)23.90
P/FCF Ratio23.80
Enterprise Value/Market Cap1.22
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.83
Enterprise Value/Ebitda34.61
Forecast
1Y Price Target
$100.82Price Target Upside49.61% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering19
---
Bulls Say, Bears Say
Bulls Say
Market ExpansionDXCM expanded its prescriber base by 50k and noted record new starts, expecting that trend to continue.
Product FeaturesThe G7 15 Day sensor is now the longest lasting CGM sensor on the market at 15.5 days, offering best in class accuracy.
Regulatory ApprovalDXCM's announced FDA approval of the G7 15 Day sensor for people over the age of 18 in the US represents an incremental positive vs. expectations.
Bears Say
Competitive ChallengesThe sensor survivorship of 73.9% for the G7 15-day is below previous estimates and competitor standards.
Operational RisksThe FDA clearance came despite the outstanding warning letter.
---
Ownership Overview
0.46% Insiders
27.55% Mutual Funds
26.36% Other Institutional Investors
15.65% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
DXCM FAQ
What was Dexcom’s price range in the past 12 months?
Dexcom lowest stock price was $57.52 and its highest was $139.24 in the past 12 months.
What is Dexcom’s market cap?
Dexcom’s market cap is $25.93B.
When is Dexcom’s upcoming earnings report date?
Dexcom’s upcoming earnings report date is May 01, 2025 which is in 16 days.
How were Dexcom’s earnings last quarter?
Currently, no data Available
Is Dexcom overvalued?
According to Wall Street analysts Dexcom’s price is currently Undervalued.
Does Dexcom pay dividends?
Dexcom does not currently pay dividends.
What is Dexcom’s EPS estimate?
Dexcom’s EPS estimate is 0.33.
How many shares outstanding does Dexcom have?
Dexcom has 392,107,500 shares outstanding.
What happened to Dexcom’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Dexcom?
Currently, no hedge funds are holding shares in DXCM
---
Dexcom Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$100.82 (49.61% Upside)
$100.82 (49.61% Upside)
Blogger Sentiment
Bullish
DXCM Sentiment 75%
Sector Average 69%
Sector Average 69%
Hedge Fund Trend
Increased
By 1.7M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $432.6K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
Last 30 Days ▲ 0.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-52.62%
12-Months-Change
Fundamentals
Return on Equity
27.63%
Trailing 12-Months
Asset Growth
3.51%
Trailing 12-Months
Company Description
Dexcom
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom Real-Time API, which enables invited third-party developers to integrate real-time CGM data into their digital health applications and devices; Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions; and Dexcom Share, a remote monitoring system. The company's products candidature comprises Dexcom G7, a next generation G7 CGM system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop blood-based or interstitial glucose monitoring products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
---
DXCM Company Deck
---
DXCM Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
The earnings call presented a generally positive outlook for DexCom, with strong revenue growth, significant customer base expansion, and successful international market performance. However, challenges such as gross margin decline and operating income reduction were noted, indicating areas for improvement.Read More>---
DXCM Revenue Breakdown
71.65% U.S.
28.35% Outside of the U.S.
---
DXCM Stock 12 Month Forecast
Average Price Target
$100.82
▲(49.61% Upside)
Technical Analysis
Best Analysts Covering DXCM
1 Year
1 Year Success Rate
32/46 ratings generated profit
1 Year Average Return
+37.15%
assigned a buy rating 6 months ago
Copying Steven Lichtman's trades and holding each position for 1 Year would result in 69.57% of your transactions generating a profit, with an average return of +37.15% per trade.
---